Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Depreciation & Amortization (CF) (2016 - 2025)

Cumberland Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 30.37% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $4.1 million, down 15.45%, while the annual FY2025 figure was $4.1 million, 15.45% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.0 million at Cumberland Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.7 million in Q1 2022 and bottomed at $511483.0 in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $1.1 million (2024), against an average of $1.2 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 43.86% in 2022 against a maximum downside of 52.51% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.1 million in 2021, then crashed by 52.51% to $511483.0 in 2022, then surged by 145.5% to $1.3 million in 2023, then grew by 19.17% to $1.5 million in 2024, then plummeted by 30.37% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Depreciation & Amortization (CF) are $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025).